Loading...

CDTX CIDARA THERAPEUTICS INC Operational Disruptions 8-K Filing

CDR

CDTX

CIDARA THERAPEUTICS INC

(CDTX)

2023 8-K

Show Summary

Show Summary

Equity Offerings

Suspension of Prospectus

Product Expansion

Increase in authorized shares

Financial Statements

Financial Results

Management Changes

Management Changes

Q3 Financial Results

Clinical Trial Launch

Workforce Reduction

Financial Results

Annual Meeting Approval

Bonus Determinations for Fi...

Financial Results

Update of Presentation

License Agreement and Priva...

Asset Sale Agreement

Restatement of Financial St...

Special Meeting of Stockhol...

Nasdaq Compliance Extension

Product Approval

Financial Results

Financial Results

Annual Meeting Voting Results

Financial Results

Financial Results

Underwriting Agreements wit...

Financial Update

Phase 2a Trial Results

Compliance regained

External Links:

Cidara Therapeutics announced positive efficacy and safety data from a Phase 2a trial evaluating CD388 as a prophylactic treatment for H3N2 influenza A virus.

AI Assistant

CIDARA THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.